CN115298174A - 嘧啶并杂环类化合物及其应用 - Google Patents

嘧啶并杂环类化合物及其应用 Download PDF

Info

Publication number
CN115298174A
CN115298174A CN202180021254.XA CN202180021254A CN115298174A CN 115298174 A CN115298174 A CN 115298174A CN 202180021254 A CN202180021254 A CN 202180021254A CN 115298174 A CN115298174 A CN 115298174A
Authority
CN
China
Prior art keywords
compound
added
reaction
mol
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180021254.XA
Other languages
English (en)
Other versions
CN115298174B (zh
Inventor
张杨
伍文韬
张晶
孙继奎
徐洋洋
陈之键
金奋宇
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deshengji Pharmaceutical Wuxi Co ltd
Original Assignee
Deshengji Pharmaceutical Wuxi Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deshengji Pharmaceutical Wuxi Co ltd filed Critical Deshengji Pharmaceutical Wuxi Co ltd
Priority to CN202311017911.0A priority Critical patent/CN117050079A/zh
Priority to CN202311335558.0A priority patent/CN117510492A/zh
Publication of CN115298174A publication Critical patent/CN115298174A/zh
Application granted granted Critical
Publication of CN115298174B publication Critical patent/CN115298174B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

一类嘧啶并杂环类化合物，具体公开了式(III)所示化合物或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN202180021254.XA 2020-03-12 2021-03-11 嘧啶并杂环类化合物及其应用 Active CN115298174B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202311017911.0A CN117050079A (zh) 2020-03-12 2021-03-11 嘧啶并杂环类化合物及其应用
CN202311335558.0A CN117510492A (zh) 2020-03-12 2021-03-11 嘧啶并杂环类化合物及其应用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202010172140 2020-03-12
CN2020101721402 2020-03-12
CN202010323035 2020-04-22
CN2020103230354 2020-04-22
CN2020109532038 2020-09-11
CN202010953203 2020-09-11
CN202011593642 2020-12-29
CN2020115936429 2020-12-29
PCT/CN2021/080278 WO2021180181A1 (zh) 2020-03-12 2021-03-11 嘧啶并杂环类化合物及其应用

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202311017911.0A Division CN117050079A (zh) 2020-03-12 2021-03-11 嘧啶并杂环类化合物及其应用
CN202311335558.0A Division CN117510492A (zh) 2020-03-12 2021-03-11 嘧啶并杂环类化合物及其应用

Publications (2)

Publication Number Publication Date
CN115298174A true CN115298174A (zh) 2022-11-04
CN115298174B CN115298174B (zh) 2023-11-03

Family

ID=77670465

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202180021254.XA Active CN115298174B (zh) 2020-03-12 2021-03-11 嘧啶并杂环类化合物及其应用
CN202311335558.0A Pending CN117510492A (zh) 2020-03-12 2021-03-11 嘧啶并杂环类化合物及其应用
CN202311017911.0A Pending CN117050079A (zh) 2020-03-12 2021-03-11 嘧啶并杂环类化合物及其应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202311335558.0A Pending CN117510492A (zh) 2020-03-12 2021-03-11 嘧啶并杂环类化合物及其应用
CN202311017911.0A Pending CN117050079A (zh) 2020-03-12 2021-03-11 嘧啶并杂环类化合物及其应用

Country Status (11)

Country Link
US (2) US20230151004A1 (zh)
EP (1) EP4105211A4 (zh)
JP (2) JP2023517995A (zh)
KR (1) KR20220152295A (zh)
CN (3) CN115298174B (zh)
AU (2) AU2021233058A1 (zh)
BR (2) BR112022018140B1 (zh)
CA (2) CA3171365A1 (zh)
IL (1) IL296357A (zh)
MX (1) MX2022011283A (zh)
WO (1) WO2021180181A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
JP2022546043A (ja) 2019-08-29 2022-11-02 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｄ阻害剤
KR20220091480A (ko) 2019-09-24 2022-06-30 미라티 테라퓨틱스, 인크. 병용 요법
CA3163218A1 (en) * 2019-12-02 2021-06-10 Shanghai Yingli Pharmaceutical Co., Ltd Oxygen-containing heterocyclic compound, preparation method therefor and use thereof
IL294048A (en) 2019-12-20 2022-08-01 Mirati Therapeutics Inc sos1 inhibitors
US20220112204A1 (en) * 2020-10-14 2022-04-14 Accutar Biotechnology Inc. Substituted dihydropyranopyrimidine compounds as kras inhibitors
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
CR20230570A (es) 2021-05-05 2024-01-22 Revolution Medicines Inc Inhibidores de ras
TWI820901B (zh) * 2021-09-10 2023-11-01 大陸商德昇濟醫藥（無錫）有限公司 嘧啶並雜環類化合物的晶型及其製備方法
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
CN114539246A (zh) * 2021-12-30 2022-05-27 苏州闻天医药科技有限公司 一种哌啶并嘧啶类化合物及其用途
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2023246914A1 (zh) * 2022-06-24 2023-12-28 南京明德新药研发有限公司 杂环取代的嘧啶并吡喃类化合物及其应用
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020035031A1 (en) * 2018-08-16 2020-02-20 Genentech, Inc. Fused ring compounds
WO2020239123A1 (zh) * 2019-05-31 2020-12-03 上海翰森生物医药科技有限公司 芳香杂环类衍生物调节剂、其制备方法和应用
CN112390788A (zh) * 2019-08-13 2021-02-23 苏州闻天医药科技有限公司 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2863873T3 (es) * 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020035031A1 (en) * 2018-08-16 2020-02-20 Genentech, Inc. Fused ring compounds
WO2020239123A1 (zh) * 2019-05-31 2020-12-03 上海翰森生物医药科技有限公司 芳香杂环类衍生物调节剂、其制备方法和应用
CN112390788A (zh) * 2019-08-13 2021-02-23 苏州闻天医药科技有限公司 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途

Also Published As

Publication number Publication date
JP2024045251A (ja) 2024-04-02
CN117510492A (zh) 2024-02-06
US20240116934A1 (en) 2024-04-11
EP4105211A4 (en) 2023-09-06
BR112022018140B1 (pt) 2024-02-15
JP2023517995A (ja) 2023-04-27
US20230151004A1 (en) 2023-05-18
CN115298174B (zh) 2023-11-03
IL296357A (en) 2022-11-01
CA3171365A1 (en) 2021-09-16
MX2022011283A (es) 2022-11-16
CN117050079A (zh) 2023-11-14
AU2021233058A1 (en) 2022-10-13
BR122023026304A2 (pt) 2024-01-16
EP4105211A1 (en) 2022-12-21
BR112022018140A2 (pt) 2022-11-22
AU2024201366A1 (en) 2024-03-21
KR20220152295A (ko) 2022-11-15
WO2021180181A1 (zh) 2021-09-16
CA3232127A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
CN115298174A (zh) 嘧啶并杂环类化合物及其应用
CN112533916B (zh) 一种作用于crbn蛋白的三并环类化合物
CN105209448B (zh) 三环化合物及其用途
WO2021259331A1 (zh) 八元含n杂环类化合物
CN113474343A (zh) 作为ret抑制剂的吡唑并吡啶类化合物及其应用
CN111788205B (zh) 吡唑并嘧啶衍生物及其用途
CN112689627A (zh) 三环取代哌啶二酮类化合物
CN114728969A (zh) 作为dna-pk抑制剂的嘧啶并咪唑类化合物
KR20220059517A (ko) 소분자 pd-1/pd-l1 억제제로서의 화합물 및 이의 용도
CN112771045B (zh) 喹啉并吡咯烷-2-酮类衍生物及其应用
CN116761799A (zh) 嘧啶并吡喃类化合物
WO2022063308A1 (zh) 一类1,7-萘啶类化合物及其应用
CN115867346A (zh) 激酶抑制剂
TWI811656B (zh) 嘧啶并雜環類化合物及其應用
CN112574278A (zh) 作为蛋白降解剂杂环类化合物及其制备方法和医药应用
WO2020063965A1 (zh) 作为选择性Trk抑制剂的吡唑并嘧啶衍生物
CN112424189A (zh) 吡咯烷基脲衍生物及其在TrkA相关疾病的应用
WO2023001069A1 (zh) 大环酰胺类化合物及其应用
WO2022083687A1 (zh) 硒杂环类化合物及其应用
WO2023208127A1 (zh) 杂芳基取代的双环化合物及其应用
WO2023241618A1 (zh) 氨基嘧啶类化合物及其应用
WO2023138601A1 (zh) 桥环取代的杂芳基并吡喃类衍生物及其应用
WO2022063094A1 (zh) 四氢异喹啉衍生物及其应用
WO2024051727A1 (zh) 吡唑类衍生物、药物组合物及应用
CN116981660A (zh) 氟代乙烯基联苯衍生物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40078182

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant